Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Corvus Pharmaceuticals announced the publication of final Phase 1/1b data for soquelitinib in Blood, showing durable responses in T cell lymphoma patients. In a subgroup of 24 patients with 1-3 prior therapies, the drug achieved an objective response rate of 38% (9/24) with a median overall survival of 28.1 months and no dose-limiting toxicities.
Key figures
- Drug Name
- soquelitinib
- Phase Of Trial
- Phase 1/1b
- Selected dose
- 200 mg twice-daily
- Total patients enrolled
- 75
- Phase 3 enrollment target
- 150
- Subgroup objective response rate
- 9 of 24
- Subgroup median overall survival months
- 28.1
- Subgroup patients 1 to 3 prior therapies
- 24
- Subgroup median progression free survival months
- 6.2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.